Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
14.6%
0.25
0.35
0.73
-1.58%
-48.0%
81.99
Nifty 500 benchmark
17.2%
0.35
0.47
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
83 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
954
-43.3%
12.0%
97.3%
20%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
InvestVerdict
UTI - MNC Fund
Regular Plan · Growth
Allocation
By asset
Equity
94.63%
Cash & Equivalents
5.00%
Debt
0.37%
By market cap
Concentration
Number of stocks
60
Top 5 stocks
27.33%
Top 10 stocks
41.17%
Top 20 stocks
59.66%
Largest holding
8.44%
Largest sector
Pharmaceuticals & Biotechnology 16.42%
Effective stocks
36.4
Cash
5.00%
InvestVerdict
UTI - MNC Fund
Regular Plan · Growth · holdings
Sector split
Pharmaceuticals & Biotechnology
16.42%
Automobiles
11.19%
Auto Components
10.41%
Food Products
9.33%
IT - Software
8.32%
Industrial Products
5.61%
Diversified FMCG
5.02%
Cash & Equivalents
4.77%
Consumer Durables
4.41%
Personal Products
2.67%
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹759,275
₹159,275
9.36%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 29 Aug 2026.